Doxycycline Could Enhance Interferon Beta 1-a (Avonex) Therapy in Remitting Relapsing MS: Presented at ECTRIMS
By Bruce Sylvester
THESSALONIKI, GREECE -- October 4, 2005 -- Interim findings from an ongoing study suggest that the addition of oral doxycycline to interferon beta 1-a (Avonex) therapy for patients with relapsing remitting multiple sclerosis (RRMS) results in statistically significant reduction of gadolinium enhancing (Gd+) lesions compared to interferon beta 1-a monotherapy. "We saw a great reduction in gadolinium enhancing lesions over the period of 4 months after we introduced oral doxycycline to interferon treatment with Avonex.....................We are hopeful that this combination treatment will prove to greatly reduce relapse rates among these patients, who are all relapsing remitting patients," said investigator Rhonda Brooks, Clinical Research Coordinator, Louisiana State University Medical Center, Baton Rouge, Louisiana, United States.
A slight failure to join all the dots, methinks.